Paris, France-based Sofinnova Partners has raised €240m (approximately $312m) for its seventh venture capital fund dedicated to the life sciences.
Sofinnova Capital VII has received support from pension funds, fund of funds and insurance companies including the European Investment Fund, Skandia Life Insurance Company, CNP Assurances, and CDC Entreprises.
The fund will focus on companies in the biopharmaceutical, medical devices and industrial biotechnology fields, investing as a founding and lead investor in corporate spinoffs, start-ups and turnaround situations.
Two third of the funds will be invested in European companies, and one third outside of Europe, most often in the USA.
FinSMEs
23/12/2012